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Abstract
One of the greatest challenges facing the development of a universal treatment for
influenza infection is the virus’s ability to mutate rapidly and produce new antigenic properties.
Targeting the viral components of one strain does not ensure that the treatment will be effective
with a newly developed strain. One alternative would be to develop therapies that target cellular
factors the virus depends on for survivability. One of these factors is the cellular SUMOylation
system. We have previously demonstrated that the Small Ubiquitin-like MOdifier (SUMO)
interacts with the influenza virus by SUMOylating several viral proteins and by affecting the
interferon blocking activity of its non-structural protein NS1. These interactions open the door to
the potential development of a treatment that would not be constrained by virus specificity. Here,
we further elucidate the ways in which the influenza virus is being affected by SUMOylation.
Through confocal microscopy experiments where components of the cellular SUMOylation
system were over-expressed through transfection, we were able to establish that with the overexpression of SUMO and the conjugating enzyme, Ubc9, cells were less likely to progress into
the late stages of infection, characterized by the presence of the late viral M1 protein therefore
suggesting a potential anti-influenza role for the cellular SUMOylation system. Furthermore,
through RNP reconstitution assays and primer extension analyses, we discovered that the
SUMOylation of NS1 plays a minor role in NS1’s ability to regulate the splicing of viral gene
transcripts. Taken together, these studies provide a deeper insight into the interplay between the
influenza virus and the cellular SUMOylation system.
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Chapter 1: Introduction
As an acute viral infection, influenza has been a long-running threat to public health (Ison
and Lee ; Taubenberger and Morens). Annual epidemics around the world will infect about 10%
of the population causing anywhere from 250,000 to 500,000 deaths (WHO). Occasionally, the
emergence of new viruses will lead to pandemics which will have a much higher mortality rate
than that of seasonal influenza (McCaughey). Within the last century, several severe pandemics
have occurred including the Spanish Influenza pandemic of 1918 that killed an estimated 50
million people worldwide, the Asian Flu pandemic of 1957 which had a death toll of roughly 1
million, and the Hong Kong flu of 1968 which was responsible for approximately 700,000 deaths
(Rajagopal and Treanor 2007).
Currently, there are two predominant ways to treat influenza; through vaccination or
antivirals. However, both approaches have their limitations. Present vaccines are able to produce
a strong antibody response to surface viral glycoproteins, haemagglutinin and neuraminidase;
however this protection relies on type, sub-type and strain specificity (Couch 2003; Hampson
2008). Antivirals, such as Zanamivir and Oseltamivir (Tamiflu), are both neuraminidase
inhibitors, yet a single amino acid change in the active site of neuraminidase can render the virus
resistant to the drug (von Itzstein 2007). Other antivirals include Rimantadine and Amantadine,
both M2-ion channel protein inhibitors. While both were proven to be effective, they were
known to cause substantial side effects in the central nervous system and many current
transmitted strains are resistant to these drugs (von Itzstein 2007).
It is evident that influenza poses a serious risk to the population and that our current
countermeasures are less than ideal. Therefore, it would be advantageous to develop a universal
treatment for influenza that utilizes the host machinery to eliminate resistance due to the ever
1

changing virus. However, we first need to dissect the interplay between the virus and host cell
mechanisms. One such mechanism is the cellular SUMOylation system. In this study, we aimed
to determine how modulating the SUMOylation system affects the ability of the virus to infect
new cells and how increasing the SUMOylation of a viral protein, NS1, affects its reported
ability to regulate splicing during infection.
1.1

The Influenza A virus
Influenza A viruses are enveloped viruses that belong to the family Orthomyxoviridae

(Cheung and Poon 2007; Samji 2009). They contain a single-stranded, segmented, negative
sense RNA genome which consists of eight segments that encode for 10 to 11 viral proteins
(Samji 2009). All eight viral RNA segments are found inside the virion bound to the
nucleoprotein (NP) and the viral polymerase complex, made up of PB1, PB2 and PA, to form
ribonucleoprotein (RNP) complexes (Cheung and Poon 2007).
The viral life cycle can be divided into several stages: entry into the cell, entry of vRNPs to the
nucleus, transcription and replication of the genome, export of the vRNPs and assembly and
budding at the plasma membrane (Samji 2009). During entry, haemagglutinin binds to sialic acid
receptors on the host’s cell membrane (Skehel and Wiley 2000). Once bound, the virus enters the
cell in an endosome through receptor mediated endocytosis (Samji 2009). Acidification of the
viral particle caused by the opening of the M2 ion channel causes the fusion of the viral
membrane with the endosomal membrane (Holsinger, Nichani et al. 1994). This fusion
consequently causes the release of the vRNPs away from the viral matrix protein, M1, in to the
host cell’s cytoplasm (Samji 2009). Once released, the vRNPs enter the nucleus by utilizing a
nuclear localization signal that is present in NP, PA and PB2 (Fodor and Smith 2004).
Replication of the viral genome results in the generation of full length vRNA through a cRNA
2

intermediate. The vRNA segments are used as templates for transcription and further replication.
Some vRNA transcripts are exported out into the cytoplasm as RNPs where they will be used for
the formation of new viral particles (Nagata, Kawaguchi et al. 2008).
In transcription, mRNA is generated by directly copying the vRNA template; however,
this requires the use of a primer. PB2 protein employs a “cap-snatching” mechanism were it is
able to The cleave cellular mRNA caps and use the stolen cap to prime viral transcription (Li,
Rao et al. 2001). To achieve polyadenylation, the viral RNA dependent RNA polymerase, RdRp,
will stutter over a stretch of U residues at the 5’ end of the template (Poon, Pritlove et al. 1999).
Negative sense vRNAs are assembled into vRNPs and are exported from the nucleus where they
will travel to the site of assembly and budding at the host’s cell plasma membrane (Samji 2009).
Before viral particles are released, Neuraminidase, NA, cleaves sialic acid residues from
glycoproteins (Palese, Tobita et al. 1974). Once released, the virus will go on to infect another
cell.

3
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1.2 The NS1A and NEP Proteins
The NS1 protein of the Influenza A virus is a multifunctional protein that contributes
many roles to the virus. The protein has two distinctive domains, the RNA binding domain at the
N terminus and the effector domain at the C terminus (Wang, Basler et al. 2002; Chien, Xu et al.
2004). The RNA binding domain has been shown to bind in vitro to RNA with low affinity in a
sequence independent manner, although sequence-specific binding has also been reported (Marc,
Barbachou et al. ; Qian, Chien et al. 1995; Chien, Xu et al. 2004). The effector domain is
believed to predominantly mediate the interaction with cellular proteins but it also stabilizes the
RNA-biding domain (Wang, Basler et al. 2002). It is highly probable that the NS1 protein
occurs as a homodimer with both domains taking part in the dimerization (Nemeroff, Qian et al.
1995).
It is widely regarded that the main function of NS1 is the neutralization of the host’s
interferon response. Studies have shown that NS1 is able to prevent the activation of IRF-3,
NFκB and c-Jun/ATF, transcription factors that are essential for the induction of IFN-β (Talon,
Horvath et al. 2000; Wang, Li et al. 2000; Ludwig, Wang et al. 2002). Other studies have also
suggested that NS1 is able to block the induction of IFN-β by creating a complex with RIG-I
consequently preventing RIG-I from inducing IFN-β (Pichlmair, Schulz et al. 2006; Guo, Chen
et al. 2007; Mibayashi, Martinez-Sobrido et al. 2007; Opitz, Rejaibi et al. 2007).
An additional role for NS1 is the regulation of viral RNA synthesis. One of the primary
studies in this area used temperature sensitive mutants of NS vRNA and found decreased levels
of all the vRNA segments in infected cells, but found no changes in mRNA or cRNA levels
(Wolstenholme, Barrett et al. 1980). NS1 has also been reported to interact with the viral
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polymerase complex and to have high affinity for dsRNA that contain panhandle structures like
those found in vRNA (Hatada and Fukuda 1992; Marion, Zurcher et al. 1997).
Furthermore, it has also been reported that during infection with the influenza virus there
is a selective translation of the viral mRNAs versus cellular mRNAs (Garfinkel and Katze 1993).
Hatada et al., demonstrated that temperature sensitive influenza viruses with mutations in NS1
had a decrease in the synthesis of viral protein (Hatada, Hasegawa et al. 1990). Enami et al.
further supported this finding by showing that while NS1 does not cause a change in viral mRNA
transcription, it instead enhances the translation of viral mRNAs through a 5’-UTR-dependent
manner (Enami, Sato et al. 1994).
The splice product of the NS gene segment generates the 121 amino acid protein, NS2,
also known as the nuclear export protein, NEP (Lamb and Lai 1980). Although initially believed
to not have a structural role within the virion, small amounts of NS2 were later discovered
existing within the virion where it may interact with M1 (Inglis, Barrett et al. 1979; Yasuda,
Nakada et al. 1993). NS2 was subsequently associated with mediating the export of vRNPS from
the nucleus, which led to the protein’s renaming to NEP (Paterson and Fodor ; O'Neill, Talon et
al. 1998). Recently, studies have suggested that NEP holds more than one duty within the virus.
Some studies have exhibited data demonstrating that NEP may regulate the accumulation of
vRNA, cRNA and mRNA which may lead to a switch from viral transcription to favor the
generation of vRNPs (Paterson and Fodor ; Robb, Smith et al. 2009). Due to this function, recent
studies have implicated NEP in playing an essential role for the avian H5N1 to adapt to replicate
effectively in mammalian cells (Manz, Brunotte et al.).

6

1.3 The M1 and M2 proteins
The M1 protein is comprised of 252 amino acids and includes an N-terminal and Cterminal domain linked together by a protease-sensitive loop (Ito, Gorman et al. 1991). The M1
protein, encoded by segment 7, is the most plentiful structural protein found within the virion
(Ruigrok, Calder et al. 1989; Fujiyoshi, Kume et al. 1994). Like NS1, M1 plays several
functional roles throughout various stages of the viral life cycle (Zhang, Wang et al.). As the
matrix protein, it forms the layer bounded by the lipid membrane and the viral
ribonucleoproteins (vRNPs), guaranteeing the stability of the virion (Zhang, Wang et al. ;
Coloma, Valpuesta et al. 2009). M1 is also involved in the viral life cycle by interacting with
RNA and vRNPs through its involvement in localization, inhibition of RNA transcription and
regulating the import and export of newly generated vRNPs (Cros and Palese 2003; Liu, Sun et
al. 2009). Its role as a key structural protein deals with assembly and budding of the virus.
Through the interaction with other viral proteins, it can assemble viral like particles (VLPs),
elicit viral elements to the site of budding, as well as host components to complete budding
(Avalos, Yu et al. 1997; Ali, Avalos et al. 2000; Gomez-Puertas, Albo et al. 2000).
The M2 protein is the splice product of the segment 7 transcript and is comprised of 97
amino acids (Cross, Dong et al.). It is an integral membrane protein and exists as a
homotetramer, which has ion channel activity thus allowing it to control the internal pH of the
viral particle. M2 allows for the acidifaction of the internal area of the approaching viral particle,
which is thought to be essential for effective viral infection as it allows the vRNPs to dissociate
from M1 and be transported into the nucleus (Lamb, Zebedee et al. 1985; Wang, Lamb et al.
1994; Bui, Whittaker et al. 1996; Sakaguchi, Tu et al. 1997). It is also reported that M2
conserves a pH within Golgi vesicles that stabilizes the innate conformation of haemagglutinin
while it is being transported for use in viral assembly (Takeuchi and Lamb 1994).
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1.4 The cellular splicing machinery
In vertebrates, protein coding genes produce immature mRNA transcripts that contain
both introns and exons. where the intron areas of sequence are removed and the exons are ligated
to form the mature mRNA (Jurica and Moore 2003). The maturation of the mRNA occurs in the
nucleus where it is moved to the cytoplasm to be translated. Like many mechanisms within cells,
splicing occurs in a series of steps. Excision and joining of the introns and exons occur at
specific sequences known at splice sites. At the 5’ splice site, the consensus sequence is –
AG|GUAAGU and at the 3’ splice site it is U(C)AG| (Jurica and Moore 2003). At the 3’ end, the
splice site region has three conserved sequence elements: a branch point, a polypyrimidine tract
and a terminal AG at the end of the intron (Black 2003).
The initial steps of splicing begin with the coating of naked pre-mRNA with hnRNPs
(heterogenous ribonucleoprotein) proteins. Once this binding has occurred, the spliceosome
begins to assemble. The spliceosome contains the small nuclear ribonucleoprotein particles
(snRNPs) U1, U2, U4, U5 and U6, plus additional accessory proteins (Norton 1994; Jurica and
Moore 2003). The earliest complex characterized during spliceosome assembly is the E (early)
complex made up of U1 and the dimeric U2 auxiliary factor, U2AF. The A complex is formed
when the U2 snRNP joins the E complex. Joining of the U4/U5/U6 tri-snRNP to the A complex
creates the B complex. The B complex undergoes a substantial rearrangement and becomes the C
complex. The C complex will then catalyze the two trans-esterification events that take place
during splicing. The 5’ exon is cleaved from the intron and produces two reaction intermediates,
a detached 5’ exon and an intron fragment. The intron fragment will be attacked by the detached
exon. The ligation of the two exons will form the mature mRNA (Black 2003).
It is generally accepted that protein-RNA interactions are the main mechanisms by which
splicing is regulated (Witten and Ule). The importance of protein-RNA interactions have been
assessed through bioinformatics studies which analyzed RNA motifs to predict exon regulation
8

by the SR, Fox and NOVA proteins, all of which are known as RNA binding proteins (RBPs)
(Liu, Zhang et al. 1998).
Preliminary studies into splicing regulation revealed SR proteins as exonic splicing
enhancers (ESEs) (Liu, Zhang et al. 1998). SR proteins are highly conserved serine/arginine rich
RNA binding protiens that regulate splice site selection (Zahler, Neugebauer et al. 1993). SR
proteins are active in the early stages of spliceosome assembly by stimulating the binding of U1
snRNP to the 5’ splice site (Kohtz, Jamison et al. 1994; Staknis and Reed 1994). Conversely,
hnRNPs have been attributed to being exonic splicing silencers (ESSs) by binding to sites
equivalent to those of SR binding proteins, thereby inhibiting their enhancing effect (Mayeda and
Krainer 1992; Shin and Manley 2004). It has also been reported that the assembly of the
spliceosome participates in determining which splice site will be used. The choice of splice site
is thought to also be regulated in part by the binding of the initial factors to the pre-mRNA and
the subsequent formation of early spliceosomal complexes (Black 2003). Multiple factors play a
role in determining how splicing will occur. Any factors altering the activity of RBPs could
potentially have an effect on the regulation of splicing. Such changes may include posttranslational modifications (Witten and Ule). The mechanism by which splicing is regulated by
these elements has not yet been fully characterized. It is suggestive that concentration or activity
of these components may modify complex assembly and therefore mediate the final splicing
outcome (Shin and Manley 2004). What is evident is that RBPs play a large role in splicing
regulation (Witten and Ule).
1.5 Regulation of splicing by NS1
Apart from the many functions for NS1 already stated, there is still another that deserves
mentioning: Its ability to regulate splicing. In eukaryotic cells, only the spliced mRNA products
9

are exported from the nucleus. Influenza virus partially avoids this control because both spliced
and unspliced viral mRNAs encode proteins, therefore, some transcripts must be exported
without having undergone any processing by the splicing machinery (Robb, Jackson et al.).
During infection, splicing of NS1 and M1 is regulated so that approximately only 10% of the
transcripts are splice products. Early work done had suggested that specific viral products, more
specifically NS1, were able to regulate the production of spliced viral mRNA (Robb, Jackson et
al.). Since then, several papers have attempted to characterize what effects NS1 plays on the
splicing regulation of cellular and viral mRNAs. Many of the studies conducted agreed on the
fact that NS1 plays a role in the regulation of cellular RNA splicing. Furthermore, the majority of
the reports seemed to be in agreement that NS1 plays a role in the splicing of the M gene
segment. In a study performed by the Fodor group, it was demonstrated that in transfection
experiments where NS1 was expressed together with a plasmid encoding the M segment mRNA,
the accumulation of spliced products was decreased (Robb and Fodor). As influenza expresses
proteins from spliced and un-spliced mRNA transcripts, regulation of this mechanism would be
essential for the proper ratio of expression of both proteins (Robb and Fodor).
However, one of the questions that was also addressed by the papers was whether NS1
plays a role in its own splicing. The data published regarding this issue has not reached a
definitive answer. Two papers came to the conclusion that NS1 does have an inhibitory effect on
the splicing of its own mRNA, while two other papers disagreed with these conclusions and
found that NS1 did not have any effect on its own splicing. For example, one report by
Garaigorta and another by Fortes, stated that their results showed that NS1 inhibits the splicing
of the collinear transcript, but two additional papers by Lu and Robb reported that NS1 did not
play any role in the splicing of its own transcript (Robb and Fodor ; Fortes, Beloso et al. 1994;

10

Lu, Qian et al. 1994; Garaigorta and Ortin 2007). In Lu’s study, it was reported that the NS gene
segment was resistant to inhibition by the NS1 protein while Robb reported that the NS1 protein
had no effect on the accumulation of spliced NS mRNA (Robb, Jackson et al. ; Lu, Qian et al.
1994). A possible explanation for the discrepancies found in these studies could be attributed to
the different experimental techniques employed by each group. While all used transfection as
their method of introducing the viral gene segments into cells, several different types of cells
were used and the strain from which the gene segments were derived from also varied. Various
processes of RNA detection were also utilized. Fortes used an RNA protection assay where a
probe would anneal to an area of RNA that they were interested in, digested RNA would then be
analyzed by electrophoresis (Fortes, Beloso et al. 1994). While nuclease protection assays are
extremely sensitive, the plasmids used for this study did not provide a lot of confidence to their
expression as shown by their immunoblots. Lu also employed this method for RNA detection but
unlike Fortes, their plasmids were well tested and proven to work (Lu, Qian et al. 1994). The
studies conducted by (Robb and Fodor ; Robb, Jackson et al.) used primer extension analysis to
detect their species of RNA. Primer extension analysis used a primer that binds at the 3’ end of a
transcript where cDNA will then be synthesized through the use of a reverse transcriptase until
the 5’ end is reached. Primer extension is also a sensitive and reliable method for the detection of
RNA (Boorstein and Craig 1989). Although all methods are generally accepted as being
trustworthy, there are other factors involved that may affect the outcome of the results.
1.6 The cellular SUMOylation system
The reversible, post-translational modification of proteins by the Small Ubiquitin-like
Modifier (SUMO) protein is known as SUMOylation (Gareau and Lima ; Geiss-Friedlander and
Melchior 2007). Previous reports have shown SUMOylation to play a role in the regulation of
11

many cellular processes including cell cycle regulation, transcription, replication, DNA repair,
cellular localization and protein degradation (Gareau and Lima ; Hannoun, Greenhough et al.).
SUMO is ubiquitously expressed in eukaryotic cells, including yeast, C. elegans, and D.
melanogaster (Geiss-Friedlander and Melchior 2007). The human genome encodes for four
different homologs of SUMO, SUMO1-4 (Melchior 2000; Hay 2005). SUMO1-3 are expressed
ubiquitously within cells while SUMO4 is mainly expressed in kidneys, lymph nodes and the
spleen (Guo, Li et al. 2004; Geiss-Friedlander and Melchior 2007). Furthermore, SUMO2 and
SUMO3, largely referred to as SUMO2/3, share a 97% sequence identity, however they share
only a 50% sequence identity to SUMO1 (Geiss-Friedlander and Melchior 2007). Except for
SUMO1 and SUMO4, the other SUMO homologs are able to form SUMO chains, but a chain
will be terminated if SUMO1 binds because of its lack of a SUMOylation site (Geiss-Friedlander
and Melchior 2007). The ability of SUMO4 to be conjugated in vivo remains controversial and
therefore SUMO4 is usually not given any further consideration in most SUMOylation studies
(Owerbach, McKay et al. 2005).
SUMO is synthesized as a 101 amino acid protein with a size of about 12kDA and very
closely resembles the three dimensional structure of ubiquitin. The major difference between
SUMO and ubiquitin is due to a variable extension of 10-25 amino acids at SUMO’s N terminus
(Desterro, Thomson et al. 1997; Hay 2005). Furthermore, SUMO proteins share less than a 20%
sequence identity with ubiquitin and differ in the overall surface charge (Barry and Lock ; Hay
2005; Geiss-Friedlander and Melchior 2007). Like ubiquitin and other ubiquitin like modifiers,
SUMO is conjugated to a target protein through an enzymatic cascade that involves the
activating enzymes (E1), the conjugating enzyme (E2) and a protein ligase (E3) (Desterro,
Thomson et al. 1997; Hay 2005). The initial step of the cascade involves the processing of an
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immature form of SUMO by the SUMO protease, Sentrin-Specific Protease, or SENP, to
generate the mature form (Barry and Lock). The maturation process involves cleavage of the Cterminus of SUMO by the protease to reveal a diglycine motif where the activating enzyme, a
heterodimer made up of SAE1/SAE2, can bind (Barry and Lock). Upon the formation of the
mature protein, activation of SUMO is performed by the activating enzyme by forming a high
energy thioester bond (Hannoun, Greenhough et al.). Following this step, SUMO is transferred
from the activating enzyme to the E2 conjugating enzyme, Ubc9, which binds to SUMO through
a thioester bond established with a cysteine residue on its active site (Geiss-Friedlander and
Melchior 2007). Ubc9 has the unique characteristic of being able to recognize substrate proteins
directly; therefore the Ubc9-SUMO thioester can catalyze the formation of an isopeptide bond
between the C terminal glycine residue of SUMO and the lysine of the target protein SUMO and
the substrate protein (Hay 2005). This final stage can be facilitated by a SUMO E3 ligase, which
may provide specificity for one of the three SUMO modifiers and speed up the process of SUMO
conjugation. Typically, SUMO will be conjugated at a SUMO consensus site in the target
protein, which follows the sequence ψKXE, where ψ is any large hydrophobic residue and X is
any amino acid (Hay 2005). SUMO conjugation is a reversible modification and can therefore be
reversed through the action of SUMO proteases that function by cleaving the isopeptide bond
between SUMO and the target protein (Hannoun, Greenhough et al. ; Geiss-Friedlander and
Melchior 2007). Most of the enzymes capable of processing the immature form of
SUMO through a peptidase activity are also capable of de-conjugating SUMO from its targets
through an isopeptide activity (Geiss-Friedlander and Melchior 2007).

13
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1.7 SUMOylation and viruses
The interaction between SUMOylation and viruses has only recently begun to develop as
a significant theme within the field of virology. Considering how remarkably well viruses have
adapted to exploit their host’s cellular machinery, it was only a matter of time before viruses
were discovered to manipulate the SUMOylation system of its host cells (Boggio and Chiocca
2006).
The first viral protein discovered to be modified by the SUMOylation system was the
immediate early 1 protein (IE1) of human cytomegalovirus (HCMV). The 72kDa protein
regulates early events in the life cycle of the virus and evidence suggested that while
SUMOylation was not required for effective viral replication, it did contribute to the full activity
of the protein (Muller and Dejean 1999). Subsequent studies demonstrated that SUMOylation of
the IE1 is needed for expression of IE2, an 86 kDa immediate early protein that acts as the
predominant initiator of the virus’ lytic life cycle (Nevels, Brune et al. 2004). The Epstein-Barr
virus, a member of the herpesviridae family, was also reported to use the SUMOylation system
in order to proliferate via the SUMOylation of the immediate-early proteins BZLF1 (Z) and
BRLF1 (R) are SUMOylated (Adamson and Kenney 2001; Chang, Lee et al. 2004).
Among other viral proteins currently known to be SUMOylated is the E1 protein of the
bovine and human papilloma viruses. Interestingly, the was SUMOylation of these proteins was
found to be enhanced by the PIAS family of proteins, thus providing an example of the complex
interactions established between viruses and the cellular SUMOylation system (Rosas-Acosta,
Langereis et al. 2005). Although the initial reports of interactions between viruses and the
SUMOylation system were limited to DNA viruses, more recent studies have demonstrated that
RNA viruses also interact with this cellular post-translational modification. For instance, a more
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recent analysis by Sun determined that the polymerase (P) protein of the parainfluenza virus 5 is
SUMOylated. This report indicated that SUMOylation of the P protein could play a role in
regulating gene expression as a mutation at a lysine residue thought to be a SUMOylaiton site
affected viral RNA transcription (Sun, Xu et al.). An investigation into the picornaviridae family
also reported that the activity of the 3C protease protein could be diminished when SUMOylated
(Chen, Chang et al. 2011). Upon further research, it was determined that upon mutation of the
SUMOylation site, apoptosis induced by the virus was down-regulated, causing reduced amounts
of the virus (Chen, Chang et al. 2011).
More recently, our group was able to find a direct link between Influenza and
SUMOylation (Pal, Rosas et al.). Data from these studies have shown that several viral proteins
are modified by SUMO (Pal, Santos et al.). Furthermore, several studies have been conducted to
analyze the importance of the SUMOylation of NS1 within the virus. Site-directed mutagenesis
tests have mapped the SUMOylation sites to residues K70 and K219. Results have shown that
the SUMOylation of NS1 affect its major function, the ability to neutralize interferon. It was
further discovered that while it does not affect stability or localization, there seems to be an
optimal level of SUMOylation of NS1 that is required to occur in order for the protein to
function at its peak (Santos, Pal et al.)
1.8 The Artificial SUMO Ligase (ASL)
The Artificial SUMO Ligase (ASL) was designed by a previous member of the lab to
specifically enhance the SUMOylation of NS1. This construct which codes for the amino acid
residues 1-87 of NS1 fused to the full length amino acid sequence of Ubc9 was designed with the
expectation that such a fusion protein of the N-terminal RNA binding domain of the PR8 NS1
with the SUMO conjugating enzyme, Ubc9, would increase the SUMOylation of NS1 by the
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interaction between the N-terminal region of NS1 and the N-terminal region of the NS1-Ubc9
fusion. This contact was expected to place Ubc9 in the immediate vicinity of the C-terminal
domain of NS1, consequently facilitating the SUMOylation of NS1 at position K219, the main
SUMOylation acceptor site in NS1. Furthermore, as it had bee previously shown that the RNA
binding domain is responsible for the protein’s IFN blocking activity, a mutant form of the ASL
was designed to include two mutations in the RNA binding domain, R38A and K41A, which
prevent RNA binding. This RNA binding domain mutant ASL has been shown experimentally to
intensify the SUMOylation of NS1 while not exhibiting any self-SUMOylation and not
appearing to stimulate the SUMOylation of any other viral or cellular protein (Santos, Pal et al.).

1.9 The overall aim of this study
This study was aimed at achieving three main goals: 1) Determine whether an over active
SUMOylation system affects influenza viral infection; 2) Determine whether the SUMOylation
of NS1 plays a role in its ability to regulate the splicing of the M gene segment; and 3)
Determine if the SUMOylation of NS1 plays a role in its ability to regulate the splicing of its
own co-linear transcript. Through the execution of this study we have discovered that upregulating the cellular SUMOylation system through transfection prevents the simultaneous
expression of the late viral protein, M1. We also fount that while influenza infection triggers a
global interaction occurring between the influenza virus and the cellular SUMOylation system,
the data collected indicates that the SUMOylation of NS1 is not critical for its splicing regulating
activity. However, this is only one piece of the puzzle of how the SUMOylation system and the
influenza virus are interacting, and while it may barely begin to scratch the surface of what is
truly occurring between these two elements, this report will provide a closer look into their
interaction and present an opportunity for further areas to be explored.
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Chapter 2: Materials and Methods
2.1 Cells and viruses used: HEK293FT cells (Invitrogen Corp., Carlsbad, CA) were maintained
in complete medium comprising of 1x Dulbecco’s Modified Essential Medium (DMEM)
supplemented with high glucose, L-glutamine, sodium pyruvate and 10% fetal bovine serum.
Geneticin (Invitrogen Corp.) was added at a final concentration of 500μg/mL. Hek293A cells
(Invitrogen Corp.) were also maintained in complete media comprising of 1x Dulbecco’s
Modified Essential Medium (DMEM) supplemented with high glucose, L-glutamine, sodium
pyruvate and 10% fetal plex. Cells were maintained at 37°C and 5% CO2. Influenza A/PR/8/34
(H1N1) was a gift from Dr. John M. Quarles (Dept. of Microbial and Molecular Pathogenesis,
College of Medicine, Texas A&M Health Science Center). Viruses were used at an MOI of 10
for immunofluorescence assays.

2.2 Plasmids: The pcDNA3/PolII/T7T7NS-ΔSpl and the pcDNA3/PolII/T7T7 (K70AK219A)ΔSpl were developed by inserting a mutation in the splicing acceptor site located within the NS
gene segment through site-directed mutagenesis. The A/WSN/1933 pPol1/WSN/M plasmid was
provided by Yoshihiro Kawaoka (Department of Pathobiological Sciences, School of Veterinary
Medicine,

University

of

Wisconsin-

Madison,

Madison,

Wisconsin).

The

pPol1/WSN/T7T7NS(R38AK41A) plasmid and the Artificial SUMO Ligase (here referred to as
ASL) were developed as previously reported (Santos, Pal et al.).

2.3 Transient Transfection: HEK293FT cells were seeded at a density of 1.8x105 cells/well into
a 24-well plate, 8.0x105 cells/well into a 6-well plate, or 10,000 cells/well for a 96 well plate.
Following the plating, 24 hours later, the cells were transfected by liposome-mediated
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transfection using the desired combinations of the plasmids and TransIT-LT1 (Mirus Bio LLC,
Madison, WI) according to the manufacturer’s instructions. For the 24-well plate, a total of 3 μg
total of DNA and 6 μL of TransIT-LT1 reagent were used per well. Similarly, 12 μg of DNA and
24 μL of TransIT-LT1 were used per well for the 6-well plate and 100ng of DNA and 0.2μL of
TransIT-LT1 per well for the 96-well plate. At the appropriate times post-transfection, total cell
extracts for Western Blotting were collected by adding boiling 2x Sample Buffer (24mM Tris
[pH 6.8], 5% Glycerol, 2% SDS, 0.01% Bromophenol Blue). For RNA purification, the cells
were trypsinized with TrypLE Express (Life Technologies, Corp.), then spun down at 5,000 x
RPMs for 5 minutes and then resuspended in sterile1x phosphate buffered saline (PBS).

2.4 Immunoblot Analyses: Cell extracts were passed numerous times through a 29 ½ gauge
needle to break down genomic DNA and decrease the viscosity of the samples. Afterwards, βmercaptoethanol was added to each sample to a final concentration of 10%. Samples were then
boiled for three minutes. Hand-made 10% SDS-PAGE gels were used to resolve the samples.
The proteins were then transferred onto Immobilon-FL (Millipore Corp., Bedford, MA) to be
detected with IRDye-conjugated secondary antibodies (LI-COR Biosciences, Inc., Lincoln, NE)
and infrared fluorescence imaging.

2.5 Infrared Fluorescence Imaging: The Immobilon-FL membranes were washed three times in
1x PBS, then blocked in Odyssey Blocking Buffer (OBB) (Li-COR Biosciences, Inc.) for an
hour at room temperature. Primary antibody was diluted in OBB supplemented with 0.1% Tween
20 (TOBB) at 4°C overnight. Following incubation with primary antibody, the membranes were
washed four times with 1x PBS supplemented with 0.1% Tween 20 (TPBS), then incubated for
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one hour at room temperature with the highly cross-absorbed IRDye 800 CW and IRDye 680 LT
conjugated secondary antibodies (Li-COR Biosciences Inc.) diluted in TOBB at a dilution of
1:20,000. The membranes were then washed 3 times with 1x TPBS and twice again with 1x
PBS. Following the washes, the membranes were scanned on an Odyssey CLx infrared imaging
system (Li-COR Biosciences Inc.). Quantification was done through the Odyssey Infrared
Imaging System Application software version 3.0.29 (LI-COR Biosciences Inc.). Statistical
analyses and graphics of the data were generated by using GraphPad Prism version 5.04 for
Windows (GraphPad Software Inc.).
The following dilutions were utilized for the various primary antibodies used for
immunoblotting: Anti-T7 tag mouse monoclonal antibody (MAb)(Novagen, EMD Biosciences
Inc., San Diego, CA) at a 1,2000 dilution, anti-Ubc9 rabbit MAb EP2938Y (Abcam, PLC,
Cambridge, MA) at a 1:2500 dilution, anti-glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) mouse MAb 2D4A7 (Santa Cruz Biotechnology Inc., Santa Cruz, CA) at a 1:5000
dilution, anti-Influenza A M1 mouse monoclonal (MAb)(Santa Cruz, Biotechnology Inc., Santa
Cruz, CA) at a 1:2500 dilution, anti-Influenza A M2 mouse monoclonal MAb (Pierce
Antibodies, Thermo Scientific Inc., Rockford, IL) at a 1:5,000 dilution.

2.6 Immunofluorescence Analysis: Once transfected with the indicated plasmids, the cells were
incubated at 37°C in 5% CO2. At 24 hours post-transfection the cells were infected, and 18 hour
post-infection the cells were fixed with 1x PBS plus 4% paraformaldehyde for 10 minutes at
room temperature, permeabilized by incubation with 100% Methanol for 10 minutes at room
temperature and washed twice with 1XPBS. The cells were incubated in blocking solution (1x
PBS plus 1% Goat Serum) for an hour at room temperature, and cells were subsequently

20

incubated for two hours at room temperature with primary antibodies, all diluted at 1:500 in
blocking solution. Primary antibodies used were anti-Ubc9 rabbit MAb EP2938Y (Abcam, PLC,
Cambridge, MA), anti-Influenza A M1 mouse monoclonal (MAb)(Santa Cruz, Biotechnology
Inc., Santa Cruz, CA) and anti-β-Galactosidase rabbit PAb (Pierce Antibodies, Thermo Scientific
Inc., Rockford, IL). Primary antibody was removed and cells were washed three times with 1x
PBS. Fluorescently labeled secondary antibodies Alexa Fluor 488 goat anti-mouse IgG and
Alexa Fluor 594 goat anti-rabbit IgG (both from Molecular Probes, Life Technologies Corp.,
Carlsbad, CA) were added to the cells diluted 1:500 in blocking solution and incubated for two
hours at room temperature. The cells were washed three times with 1x PBS then stained with
4’,6-diamidino-2-phenylindole (DAPI) (Molecular Probes) for 5 minutes then washed once again
three times in 1XPBS. Images were captured using an LSM 700 confocal microscope (Zeiss,
New York, NY) with a 40x objective and three lasers at 405nm (DAPI), 488nm (Alexa Fluor
488), and 555nm (Alexa Fluor 594). Image acquisition was performed by using ZEN 2009
software (Zeiss, New York, NY). The ZEN 2009 software was used to add pseudocolor to the
images since the microscope system outfitted with a monochromatic camera.

2.7 Primer Extension Analysis: RNA was purified using the RNeasy Mini Kit and the
Qiashredder system (Qiagen, N.V.) following the manufacturer’s protocol. Total RNA was
analyzed through a 1% agarose formaldehyde gel and quantified using Quantity One 1-D
Analysis Software (Bio-Rad Laboratories, Inc.) and normalized to equal concentrations. Primer
extension reactions were completed using the Primer Extension System- AMV Reverse
Transcriptase (Promega Corp.), following the manufacturer’s protocol, and using the primers
presented in figures 4 and 7. The sequencing reactions were performed using the same primers
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used for primer extension analyses, and the Sequenase Version 2.0 DNA sequencing Kit (USB
Corporation, Affymatrix Inc.) following the manufacturer’s protocol. Transcription products
were analyzed on 6 % polyacrylamide gels containing 7 M urea (RapidGelTM-XL-6% Liquid
Acrylamide Ultrapure MB Grade, USB Corp., Affymatrix, Santa, CA) in TBE buffer (TrisBorate-EDTA, Fisher Scientific International Inc.). The gel was scanned on an Odyssey CLx
infrared imaging system (Li-COR Biosciences Inc.) and quantified using the Odyssey Infrared
Imaging System Application software version 3.0.29 (LI-COR Biosciences Inc.). Statistical
analyses and graphics of the data were generated by using GraphPad Prism version 5.04 for
Windows (GraphPad Software Inc.).
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Chapter 3: Results and Discussion
3.1 Over-expression of the SUMOylation system prevents influenza from progressing to late
stages of infection:
Previous work by our group demonstrated that influenza virus establishes a complex
interaction with the cellular SUMOylation system during infection. However, the molecular
intricacies and consequences of these interactions remain to be characterized. Among others, one
important question that we considered of high relevance was to establish whether the influenza
virus is affected when the cellular SUMOylation system is altered. To this end, we decided to
evaluate whether over-expression of Ubc9 alone, or Ubc9 and SUMO1 simultaneously altered
the likelihood of an infected cell being able to progress to the late stages of viral infection,
characterized by the expression of the late viral protein M1, an indicator of the successful
progression to the late stages of infection. To this end, HEK293A cells were transfected with
various combinations of expression plasmids for β-galactosidase, an HA tagged form of Ubc9,
and the dicistronic plasmids SUMO1/IRES/Ubc9 and SUMO3/IRES/Ubc9 (which code for
SUMO1 and SUMO3 respectively). At 24 hours post-transfection, the cells were infected with
A/PR8/34 H1N1 at an MOI of 10. At 14 hours post-infection, the cells were fixed and analyzed
by immunofluorescence using a mouse monoclonal antibody against M1 to detect infected cells
and a rabbit polyclonal antibody against Ubc9 to indentify cells over-expressing Ubc9. Alexa
488 Goat anti-mouse and Alexa 594 Goat anti-rabbit secondary antibodies were used. A rabbit
polyclonal antibody against β-galactosidase was also used, and the cell nuclei were stained with
DAPI. Representative images are shown in Figure 3, images are of cells stained with DAPI, the
indicated primary antibody, and the merged images. N values indicate total number of cells
counted. Cells were counted and tallied as belonging to one of the following four groups: cells
expressing high levels of Ubc9 only, cells expressing M1 only, cells expressing both Ubc9 and
M1 or cells that did not express either of these proteins. Because 10 wells within a 96 well plate
were being used for each condition, it was not necessary to repeat each individual experiment.
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Instead, what was needed was a large number of cells to be counted. A few thousand cells were
counted by hand per condition to provide for a large sample size to be evaluated. A large sample
size would diminish the probability that any effects that were noticed would be due to a random
occurring event. Chi-square and p-values were calculated by inserting these values into a chisquare calculator.
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As shown in Figure 3B, the observed frequency of cells that simultaneously co-expressed
M1 and high levels of Ubc9 and SUMO was significantly lower than expected if the two events
were independent from each other, as evidenced by the chi-square and p values calculated. This
effect was greater when SUMO3 was the SUMO isotype overexpressed. The high Chi-square
values obtained and low p values indicate that the results obtained are not due to pure chance but
instead indicate a strong co-dependency between the two characteristics observed (expression of
the late viral protein M1 and high co-expression of Ubc9 and SUMO). Specifically, the data
indicates that cells over-expressing Ubc9 and SUMO have a dramatically decreased likelihood of
progressing to the late stages of infection (i.e. expression of M1). The relatively small p-value
would imply that these changes are statistically significant. In contrast, over-expressing Ubc9
alone was not enough to confer this unique characteristic onto the cell, as the differences in Chisquare values and p-values do not differ from those in the β-galactosidase control.
It is evident that multiple elements of the complex SUMOylation machinery are engaging
with the influenza virus during infection. This data suggests that over-expression of the two
components of the SUMOylation system tested (SUMO and Ubc9), conveys to the cells a
protective effect that prevents influenza from progressing into the late stages of infection. This is
the first set of data suggesting a protective effect mediated by the SUMOylation system during
influenza infection. Other confocal microscopy studies conducted in our lab have shown that
during infection there is an overall increase in SUMO expression. However, the cells exhibiting
this over-expression of SUMO are cells directly adjacent to cells that are express M1 (i.e. cells in
late stages of infection), but no increase in SUMO has been observed in the cells that show M1
expression. In view of the data presented here, it is now possible to postulate that the global
increase in cellular SUMOylation previously reported by our laboratory may therefore be playing
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an antiviral, keeping the cell from allowing influenza virus infection to progress to the late stages
of infection. This data complements our recently published data regarding the effects of
SUMOylation on NS1’s ability to neutralize interferon. We reported that modifying the
SUMOylation of NS1, either increasing it through the use of ASL, or decreasing it through the
use of a non-SUMOylatable form of NS1, results in a decrease in NS1’s ability to neutralize the
IFN response. Thus it is likely that an overactive SUMOylation system may exert numerous
effects that contribute to an overall antiviral activity, including a SUMO-associated decrease in
NS1’s anti-IFN activity. In summary, the data presented here suggests that there is an interplay
between the SUMOylation system and influenza where simultaneous over-expression of Ubc9
and SUMO prevents the cell from progressing to the late stages of infection.

26

3.2 SUMOylation of NS1 exerts a minimal effect on the splicing regulation ability of NS1 on
the M gene segment.
As mentioned earlier, NS1 was reported to regulate splicing of mRNA transcripts. AS
NS1 is one of the most highly SUMOylated influenza proteins, and SUMOylation is known to
exert numerous effects on its targets, we wanted to determine whether SUMOylation affected
NS1’s ability to regulate the splicing of the M gene segment. To this end, we performed
quantitative infrared primer extension assays to analyze the amount of spliced and unspliced
mRNA produced from the M gene segment in the presence of normal, increased and decreased
levels of SUMOylated NS1. To detect spliced and unspliced M gene mRNA products, two 680
IRDye® Infrared Dye labeled primers were created, an M-174 primer and an M-900 primer,
which together enabled the detection of the M1 and M2 mRNAs, respectively, as shown in
Figure 4 (the unspliced co-linear mRNA produced from the M gene codes for the M1 whereas
the spliced product codes for M2).

HEK293FT cells were co-transfected with various combinations of plasmids encoding
the viral RdRp, a PolI driven plasmid encoding for the M gene segment, a PolII driven plasmid
that encode for a T7 tagged non-spliceable wild-type form of NS1 (T7T7NS1ΔSpl), or a non27

spliceable, non-SUMOylatable form of NS1 (T7T7NS1DMΔSpl), and the artificial SUMO ligase
to specifically increase the SUMOylation of NS1. Total RNA was harvested 24 hours posttransfection using the Qiagen RNeasy mini kit. The total RNA purified was quantified by
agarose formaldehyde gel. Upon quantification, all RNAs were diluted to equal amounts and
then analyzed by primer extension analysis. Total cell extracts were also collected and analyzed
by Western Blotting to check the presence of SUMOylated NS1. All data presented correspond
to the quantitative values collected in two independent experiments. Figure 5A confirms that
NS1 is being SUMOylated by the appearance of a band around 40 kDa that is not present in
samples that do not contain the NS1 PolII driven plasmid. The production of M1 and M2 are also
confirmed by the appearance of bands around the 28kDa and 15kDa sizes. Successful
transfection of the ASL is also shown by the band at 25kDa in the appropriate samples. Figure
5B demonstrates the percent of NS1 that is SUMOylated compared to total NS1. There is no
SUMOylated NS1 within the first two samples as NS1 was not present. The amount of NS1 that
is SUMOylated without any additional assistance was about 0.3% of the total. With the ASL,
SUMOylation increased to almost 4%. The non-SUMOylatable NS1 showed about a 0.2%
SUMOylation, which increased to 1.8% with the ASL. This is due to the existence of alternative
SUMOylation sites within NS1 that allow for some residual NS1 SUMOylation to take place in
the presence of the K70AK219A mutations. Figure 6A demonstrates that the primers designed
are detecting the correct mRNA species. The correct mRNA species were determined by
comparison with a sequencing ladder produces using the same primers used in the primer
extension analyses (not shown). Moreover, the GAPDH product shows an approximately equal
signal among all samples, thus indicating that very similar amounts of mRNA were used across
all samples. Figure 6B presents the quantitative differences in spliced versus unspliced mRNA
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obtained under the different NS1 conditions. While there is an increase in the total amount of
splicing that is shown when NS1 is present, there does not seem to be any significant changes in
the amount of splicing occurring when comparing the samples where SUMOylation of NS1 is
increased or decreased. However, this data is contrary to what had been seen in an earlier report
by Robb (Robb, Jackson et al.). Their study determined that NS1 inhibited the splicing of the M
gene segment, as they found lesser amounts of M2 mRNA when NS1 was present, as compared
to the amounts of M2 mRNA that did not have the addition of NS1 (Robb, Jackson et al.). In our
studies we see an obvious increase in spliced products when NS1 is added to the system. While
there does not seem to be a significant difference in the amount of splicing across all conditions,
there seems to be a slight increase in the production of M2 effect NS1 is hyper-SUMOylated.
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3.3 SUMOylation of NS1 does not play a role in the splicing regulation of the NS gene
segment
The NS gene segment transcript of the influenza genome undergoes splicing as well. The
collinear unspliced mRNA produced from the NS gene segment codes for the NS1 protein, while
the spliced product codes for the NEP protein. As NS1 has been reported by some groups to have
the ability to modulate the splicing of its own transcript, we considered it important to evaluate
what role, if any, was played by the SUMOylation of NS1 on the regulation of the splicing of the
NS transcript. Once again, we performed quantitative infrared primer extension assays to analyze
the amount of spliced and unspliced mRNA produced from the NS gene segment in the presence
of normal, increased or decreased levels of SUMOylated NS1. To detect these spliced and
unspliced mRNA species, two primers were created, an NS-171 800 IRDye® Infrared Dye
labeled primer for the detection of NS1 and an NS-658 680 IRDye® Infrared Dye labeled primer
to detect NEP mRNA, as shown in Figure 6.

Using the same methodology as before, HEK293FT cells were co-transfected with
plasmids encoding the viral RdRp, a PolI driven plasmid encoding for the NS gene segment, a
PolII driven plasmid that encodes for a T7 tagged non-spliceable wild-type form of NS1
(T7T7NS1ΔSpl), or a nonspliceable and non-SUMOylatable form of NS1 (T7T7NS1DMΔSpl),
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and the artificial SUMO ligase to specifically increase the SUMOylation of NS1. Total RNA was
harvested 24 hours post-transfection using the Qiagen RNeasy mini kit and analyzed by primer
extension analysis. Total cell extracts were also collected and analyzed by western blotting to
check the presence of SUMOylated NS1, however a suitable western blot could not be obtained
at this time. The quantitative RNA data presented corresponds to two independent experiments.
Interestingly, when dealing with the NS gene segment, we found the opposite effects of
occur when compared to the splicing of the M gene segment. Addition of NS1 seems to decrease
the amount of NS mRNA splicing. When the NS gene segment is transfected alone, the percent
of spliced product generated is about 10% of the unspliced transcript. This is the amount usually
seen under wild-type conditions. The addition of the NS1 protein into the system causes a slight
decrease in splicing. Introduction of a non-SUMOylatable form of NS1 causes only a minimal
change in the amount of splicing that occurs. On the other hand, when NS1’s SUMOylation is
artificially increased with the use of the ASL, the decrease in NS splicing becomes more
pronounced.
This data is in contrast to the study by Robb et al. who found that there were no changes
in the amount of splicing when NS1 was introduced into an RNP reconstitution assay (Robb,
Jackson et al.). Here, there does seem to be a greater effect in the amount of spliced transcript
when NS1 is hyper- SUMOylated. However, this change is opposite to what was seen with the M
gene segment. Where the splicing of the M gene segment was increased, the splicing of the NS
gene segment decreases overall. Mutation of the SUMOylation sites within NS1 does not seem
to affect the amount of splicing, with or without the ASL.

33

34

3.4 Discussion
The data obtained to date shows that SUMOylation of NS1 may play a minor role in
NS1’s regulation of splicing. SUMOylation of NS1 may have a more dramatic role in the
creation of the NEP spliced product as there was a more marked effect in the splicing of the NS
gene segment. The explanation behind this phenomenon may relate back to how splicing is
regulated.
It could be postulated that SUMOylation of NS1 prompts NS1 to become a splicing
silencer. Many exon splicing silencers contain an RNA-binding domain, such as that present in
NS1 (Wang and Burge 2008). Binding of NS1 to mRNA could be preventing the binding of
other RBPs that facilitate splicing. SUMOylation has also been known to modify protein-protein
interactions of its target protein (Geiss-Friedlander and Melchior 2007). Perhaps SUMOylation
of NS1 allows it to establish an interaction with splicing receptors, such as those of the hnRNP
class. PTB, an hnRNP can block the interactions between U1 and U2, thereby inhibiting the
formation of the spliceosome and the subsequent splicing of a transcript (Wang and Burge 2008).
Moreover, as previously mentioned, protein-RNA interactions play a significant role in
mediating how splicing occurs. It has already been determined that RBPs undergo several
posttranslational

modifications,

including

phosphorylation,

arginine

methylation

and

SUMOylation. hnRNP C, which plays a direct role in mRNA splicing, was shown to be modified
by SUMO, and it was postulated that this modification could be facilitating a role involved in
protein-protein and protein-RNA interactions (Vassileva and Matunis 2004). The same study
determined that SUMOylation was able to significantly alter hnRNPs binding to nucleic acids.
This effect would prevent hnRNPs from competing for binding with SR proteins, thereby
causing an enhancement to splicing. It could be hypothesized that a similar effect would be
occurring with NS1. SUMOylation of NS1 may be causing it to have an
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inhibitory or enhancing effect on splicing which would be sequence dependent as we see two
different effects for distinct transcripts. Furthermore, as it’s possible that NS1 may be present at
the location where splicing is occurring and the addition of the ASL may be causing the
SUMOylation of nearby RNA binding proteins, causing a change in splicing regulation.
SR proteins have also been established as associating with influenza. One study
determined that over-expression of SR proteins inhibited H5N1 NS mRNA splicing. However,
H1N1 segments did not appear to be affected by adjusted SR protein concentrations. This study
suggested that regulation of splicing in influenza is regulated differently strain to strain
(Backstrom Winquist, Abdurahman et al.). They determined different levels of NS1 mRNA
across several different strains of virus. This could also be subtype specific as reported by our
data. While both gene segments were from an H1N1 virus, the gene segments came from
different subtypes. Furthermore, the NS gene segment of H1N1 is said to be inefficiently spliced
causing a greater production in the amount of the NS1 protein which is linked to determining the
pathogenic properties of a virus (Backstrom Winquist, Abdurahman et al.).
Because splicing itself has not been fully elucidated, it is difficult to say with absolute
certainty what is occurring in this process when SUMO and NS1 are brought together.
SUMOylation of NS1 may be stimulating NS1 as an exonic splicing silencer by intensifying its
RNA binding ability and thereby preventing splicing enhancers from binding to RNA,
consequently causing decreased amounts of splice products. Conversely, it could also be
proposed that SUMOylation of NS1 is causing NS1 to act as an enhancer by boosting its proteinprotein interaction. While it has not been shown, perhaps SUMOylated NS1 is able to bind to SR
proteins thereby expediting the binding of SR proteins to RNA and therefore causing an
increasing in the production of spliced products.
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While it is evident that there are definitive changes occurring in the regulation of splicing
when the SUMOylation of NS1 is modified, the mechanistic actions behind this occurrence are
still unknown. It’s possible that NS1 represses its own splicing to allow enough NS1 production
but then enhances M1 splicing to speed up the viral release during the late stages of infection.
Further in depth studies into splicing regulation and NS1 SUMOylation would need to be
conducted before an answer could be reached. However, the data presented here gave slight
insight into how this cellular post-translational modification is interacting with the influenza
virus.
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Chapter 4: Summary, Conclusions and Future Directions
4.1 Summary and conclusions
Influenza infection continues to be a severe threat to the population with annual epidemics
affecting about 10% of the world’s population. The emergence of rapidly changing lethal viruses
makes the importance of developing a generalized therapeutic more critical. Our current
treatments, antivirals and vaccinations have a very limited effective range in relation to the
spectrum of existent viral strains because of this high dependence upon specific to viral proteins.
Because of the error prone characteristic of the viral RdRp, many treatments become obsolete
within a short period of time. A new vaccination is required every year to protect against newly
emerging strains and many currently circulating strains are now resistant to the available
antivirals. With influenza causing between 250,000 to 500,000 deaths per year, and the
likelihood of a pandemic becoming more and more probable. There is an urgent need for a more
effective wide spectrum treatment for this disease. It is evident that a novel treatment is
necessary, and perhaps it is time to target a cellular system that the virus is dependent on to halt,
or impair, its replication. As already mentioned, influenza has already been confirmed to interact
with the SUMOylation system, and has been shown to modulate the interferon blocking activity
of NS1 (Santos, Pal et al.). Here, we provide further insight into how the SUMOylation system
may play a role in influenza infection. There is evidence presented that points towards
SUMOylation offering cells a protective quality when SUMOylation components are increased.
Under such conditions, infection could not progress to the late stages of infection; hence likely
preventing virus is budding and spreading. Therefore, modulating the SUMOylation system may
be able to limit the infection and turn it into a minor disease. Furthermore, we also determined
that SUMOylation plays a minor role in affecting how NS1 regulates splicing. It seems that overSUMOylation of NS1 causes an alteration in how much splicing occurs. This could have adverse
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effects for the virus as the proportion of the different components needed to create an infective
viral particle are relatively restricted, any change in this process could potentially have
antagonistic effects on the virus and potentially increase the release of noninfectious viral
particles.
4.2 Future Directions
With the new insights into how the SUMOylation system interacts with influenza virus,
many new areas of study have been opened as a consequence. Analyzing the underlying
mechanism for why increasing the levels of SUMO and Ubc9 prevents cells from expressing M1
will need to be studied with a closer look. The many other functions of NS1 will have to be
examined to determine if SUMOylation plays any role in those functions. With every new study
conducted, it will bring us closer and closer to an answer for what function SUMOylation serves
within influenza infection. There are many other areas to look at, such as how SUMOylation is
affecting other viral proteins that become SUMOylated. Perhaps one of these interactions will
lead us to develop the elusive universal treatment for this disease.
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